Cargando…

Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy

Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Xiaoming, Zhang, Hangtian, Zhu, Ying, Liang, Yuqing, Yuan, Zhuolin, Li, Jiachen, Li, Jing, Li, Xin, Jia, Yifan, He, Tian, Zhu, Jiangyuan, Sun, Yu, Jiang, Wengting, Zhang, Hui, Wang, Cheng, Ke, Zunfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982393/
https://www.ncbi.nlm.nih.gov/pubmed/31980023
http://dx.doi.org/10.1186/s12943-020-1141-9
_version_ 1783491303919583232
author Zhong, Xiaoming
Zhang, Hangtian
Zhu, Ying
Liang, Yuqing
Yuan, Zhuolin
Li, Jiachen
Li, Jing
Li, Xin
Jia, Yifan
He, Tian
Zhu, Jiangyuan
Sun, Yu
Jiang, Wengting
Zhang, Hui
Wang, Cheng
Ke, Zunfu
author_facet Zhong, Xiaoming
Zhang, Hangtian
Zhu, Ying
Liang, Yuqing
Yuan, Zhuolin
Li, Jiachen
Li, Jing
Li, Xin
Jia, Yifan
He, Tian
Zhu, Jiangyuan
Sun, Yu
Jiang, Wengting
Zhang, Hui
Wang, Cheng
Ke, Zunfu
author_sort Zhong, Xiaoming
collection PubMed
description Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs.
format Online
Article
Text
id pubmed-6982393
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69823932020-01-29 Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy Zhong, Xiaoming Zhang, Hangtian Zhu, Ying Liang, Yuqing Yuan, Zhuolin Li, Jiachen Li, Jing Li, Xin Jia, Yifan He, Tian Zhu, Jiangyuan Sun, Yu Jiang, Wengting Zhang, Hui Wang, Cheng Ke, Zunfu Mol Cancer Review Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs. BioMed Central 2020-01-24 /pmc/articles/PMC6982393/ /pubmed/31980023 http://dx.doi.org/10.1186/s12943-020-1141-9 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhong, Xiaoming
Zhang, Hangtian
Zhu, Ying
Liang, Yuqing
Yuan, Zhuolin
Li, Jiachen
Li, Jing
Li, Xin
Jia, Yifan
He, Tian
Zhu, Jiangyuan
Sun, Yu
Jiang, Wengting
Zhang, Hui
Wang, Cheng
Ke, Zunfu
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
title Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
title_full Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
title_fullStr Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
title_full_unstemmed Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
title_short Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
title_sort circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982393/
https://www.ncbi.nlm.nih.gov/pubmed/31980023
http://dx.doi.org/10.1186/s12943-020-1141-9
work_keys_str_mv AT zhongxiaoming circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT zhanghangtian circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT zhuying circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT liangyuqing circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT yuanzhuolin circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT lijiachen circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT lijing circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT lixin circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT jiayifan circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT hetian circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT zhujiangyuan circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT sunyu circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT jiangwengting circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT zhanghui circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT wangcheng circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy
AT kezunfu circulatingtumorcellsincancerpatientsdevelopmentsandclinicalapplicationsforimmunotherapy